Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Down – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP)’s share price gapped down prior to trading on Monday . The stock had previously closed at $14.81, but opened at $14.06. Rapport Therapeutics shares last traded at $13.88, with a volume of 7,822 shares trading hands.

Rapport Therapeutics Stock Performance

The business’s 50 day moving average is $20.66.

Hedge Funds Weigh In On Rapport Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Values First Advisors Inc. purchased a new position in shares of Rapport Therapeutics during the third quarter worth approximately $31,000. BNP Paribas Financial Markets acquired a new stake in Rapport Therapeutics in the third quarter valued at $34,000. JPMorgan Chase & Co. acquired a new stake in Rapport Therapeutics in the third quarter valued at $83,000. SG Americas Securities LLC acquired a new stake in Rapport Therapeutics in the third quarter valued at $101,000. Finally, Sandia Investment Management LP acquired a new stake in Rapport Therapeutics in the second quarter valued at $116,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.